Biotherapeutics News for April 2020

Frame Therapeutics and eTheRNA immunotherapies NV open a new research collaboration to develop mRNA cancer vaccines against immunogenic neoantigens

Amsterdam (The Netherlands) and Niel (Belgium) April 22, 2020 Frame Therapeutics, a new biotechnology company focused on the development of neoantigen-based cancer vaccines, today announced that they have forged a research collaboration with eTheRNA immunotherapies NV, a clinical-stage company developing vaccines and immunotherapies from its proprietary mRNA TriMix platform.
23 April, 2020

Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine

OPENCORONA consortium awarded €3 million funding by Horizon 2020 to support emergency research and development against the COVID-19 outbreak
07 April, 2020

Biotherapeutics News for April 2020

Biotherapeutics News Archive

Frame Therapeutics and eTheRNA immunotherapies NV open a new research collaboration to develop mRNA cancer vaccines against immunogenic neoantigens Frame Therapeutics and eTheRNA immunotherapies NV open a new research collaboration to develop mRNA cancer vaccines against immunogenic neoantigens

Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine

Frame Therapeutics and eTheRNA immunotherapies NV open a new research collaboration to develop mRNA cancer vaccines against immunogenic neoantigens

Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine